Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1116

Sort by

Sort Order Select

Journal Articles

iPLA2β Contributes to Activation of Human and Mouse Platelets Via ITAM Receptors Fcγ RIIA and GPVI

Shaji Abraham, PhD, Pravin Patel, BA, Ulhas P. Naik, PhD, Steven Edward McKenzie, MD PhD

Blood (2019) 134 (Supplement_1): 2339.

https://doi.org/10.1182/blood-2019-128426

Published: 2019

Journal Articles

Pharmacological Inhibition of the RNA m 6 a Writer METTL3 As a Novel Therapeutic Strategy for Acute Myeloid Leukemia

Konstantinos Tzelepis, Etienne De Braekeleer, PhD MSc, Eliza Yankova, PhD, Justyna Rak, PhD, Demetrios Aspris, MSc, Ana Filipa Domingues, PhD, Richard Fosbeary, Alan Hendrick, PhD, Dan Leggate, PhD, Yaara Ofir-Rosenfeld, PhD, Alexandra Sapetschnig, PhD, Cristina Pina, MDDPhil, Mark Albertella, PhD, Wesley Blackaby, PhD, Oliver Rausch, PhD, George S. Vassiliou, FRCPath, MRCP, PhD, Tony Kouzarides, PhD

Blood (2019) 134 (Supplement_1): 403.

https://doi.org/10.1182/blood-2019-127962

Published: 2019

Journal Articles

A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Daniel O. Persky, MD, Vasile Musteata, MD PhD, Mamia Zodelava, MD, Tetiana Perekhrestenko, MD PhD, Adolfo E Diaz, MD, Troy H. Guthrie, Jr., MD, Thomas Strack, MD, Christine Burnett, Sarah Wilson, CCRA, Tara Baetz, MD FRCPC

Blood (2019) 134 (Supplement_1): 5324.

https://doi.org/10.1182/blood-2019-128604

Published: 2019

Journal Articles

Venetoclax Is Synergistic with Idelalisib or MK2206 Against Primary CLL Cells in an in Vitro Model of the Microenvironment

Yandong Shen, BMedSc (Hon) PhD, Kyle R Crassini, MBBS,BSc, Narjis Fatima, BSMedTech,MPhil, Richard Christopherson, PhDEmeritus Professor, Stephen P. Mulligan, PhDFRACP,FRCPA,MBBS, Oliver Giles Best, PhDBSc

Blood (2019) 134 (Supplement_1): 5443.

https://doi.org/10.1182/blood-2019-130082

Published: 2019

Journal Articles

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Christine Burnett, Thomas Strack, MD, Tara Lehner, MS, PMP, Jack P Higgins, PhD, Deborah A. Katz, MD, Matthew S. McKinney, MD

Blood (2019) 134 (Supplement_1): 5322.

https://doi.org/10.1182/blood-2019-124890

Published: 2019

Journal Articles

Inhibition of Acute Leukemia By a Small Molecule KYA1797K Which Destabilize RAS and β-Catenin

Seungmin Hahn, MD, Mi Ra Lee, Jungwoo Han, MD PhD, Moon Kyu Kim, Seung-Hwan Oh, Chuhl Joo Lyu, MD PhD

Blood (2019) 134 (Supplement_1): 5758.

https://doi.org/10.1182/blood-2019-126374

Published: 2019

Journal Articles

Identification of Tractable Drug-like eIF4Al Inhibitors with Potent Anti-Tumor Activity

Tyler A. Cunningham, BS, Derek Essegian, BS, MS, Stephan Schürer, PhD, Jonathan H. Schatz, MD

Blood (2019) 134 (Supplement_1): 5760.

https://doi.org/10.1182/blood-2019-130494

Published: 2019

Journal Articles

Dasatinib Inhibits FLT3 /ITD and PTPN11 mutated Acute Myeloid Leukemia Cells Overexpressing SRC Tyrosine Kinases

Sigal Tavor, MD, Tali Shalit, PhD, Noa Chapal Ilani, PhD, Yoni Moskovitz, PhD, Nir Livnat, BSc, Yoram Groner, PhD, Haim Bar, PhD, Alexander Plotnikov, PhD, Nathali Kaushansky, PhD, Liran I. Shlush, MD

Blood (2019) 134 (Supplement_1): 1451.

https://doi.org/10.1182/blood-2019-128016

Published: 2019

Journal Articles

Pharmacological Inhibition of MAP2K7 Induces Apoptosis and Cell Cycle Arrest in T-Cell Acute Lymphoblastic Leukemia

Taylor J Chen, BS, Ye Shen, PhD, Cory Seth Bridges, BS, Chun Shik Park, PhD, Jacob J. Junco, PhD, Karen R. Rabin, MD PhD, H. Daniel Lacorazza, PhD

Blood (2019) 134 (Supplement_1): 3889.

https://doi.org/10.1182/blood-2019-129127

Published: 2019

Journal Articles

Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax As a Therapeutic Strategy for Acute Lymphoblastic Leukemia

Christopher A. Eide, Stephen E Kurtz, PhD, Andy Kaempf, MS, Nicola Long, Jessica Leonard, MD, Bill H. Chang, MD PhD, Motomi Mori, PhD, Brian J. Druker, Jeffrey W. Tyner

Blood (2019) 134 (Supplement_1): 3950.

https://doi.org/10.1182/blood-2019-131288

Published: 2019

Journal Articles

Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma

Takashi Ishio, Joji Shimono, Sarvesh Kumar, Yuquan Lin, Emmanuel Bachy, Michael N. Petrus, Yandan Yang, Michiyuki Maeda, Hideki Goto, Satoshi Hashino, Takanori Teshima, MD, Thomas A. Waldmann, MD, Louis Staudt, MD, Masao Nakagawa

Blood (2019) 134 (Supplement_1): 3781.

https://doi.org/10.1182/blood-2019-124670

Published: 2019

Journal Articles

S-Phase Progression of North American ATLL Cells Is Critically Regulated By the Proto-Oncogene BCL6 and Targetable By PARP Inhibition

B. Hilda Ye, PhD, Elaine Chung, PhD, Kith Pradhan, PhD, Ana Acuna-Villaorduna, MD, Yanhua Wang, MD PhD, Aditi Shastri, MD, Advaitha Madireddy, PhD, Amit Verma, MBBS, R.Alejandro Sica, MD, Murali Janakiram, MD MS

Blood (2019) 134 (Supplement_1): 3779.

https://doi.org/10.1182/blood-2019-131364

Published: 2019

Journal Articles

Superior Pre-Clinical Efficacy of Novel Protac Based BET Degrader in a Large Acute Myeloid Leukemia Cohort

Malathi Kandarpa, PhD, Luke F. Peterson, PhD, Harish Potu, PhD, Yihong Liu, Avery Polk, Shaomeng Wang, PhD, Moshe Talpaz, MD

Blood (2019) 134 (Supplement_1): 3936.

https://doi.org/10.1182/blood-2019-131759

Published: 2019

Journal Articles

Efficient Elimination of Acute Myeloid Leukemia Cells through Inhibition of KDM4A in Combination with PARP Inhibition

Laura Monaghan, BSc, Matthew Edward Massett, MSc, BSc, Roderick P Bunschoten, BSc, Petrisor Alin Pirvan, MSc, BSc, Alex Hoose, Bsc, PhD, Taeju Park, BSc, Joana Bittencourt-Silvestre, BSc, MSc, Robert M J Liskamp, BSc, PhD, Heather G Jørgensen, Xu Huang, BSc, PhD

Blood (2019) 134 (Supplement_1): 3756.

https://doi.org/10.1182/blood-2019-125355

Published: 2019

Journal Articles

Targeting Neurotrophic Receptor Tyrosine Kinase (NTRK) Fusion Structural Homologs in Refractory Pediatric Acute Lymphoblastic Leukemia (ALL)

Son Tran, Mehul Gupta, Sunand Kannappan, Chunfen Zhang, MD, Aru Narendran, MD PhD

Blood (2019) 134 (Supplement_1): 3882.

https://doi.org/10.1182/blood-2019-132223

Published: 2019

Journal Articles

Targeting PRMT5 to Circumvent Acquired Ibrutinib Resistance in Mantle Cell Lymphoma

Shelby Sloan, BS, Fiona Brown, BS, JI Hyun Chung, PhD, Alexander Prouty, BS, Esther Wheeler, BS, Bonnie K Harrington, DVM, PhD, Eric Brooks, BS, Ayse S Yilmaz, MS, Hatice G Ozer, PhD, John C. Byrd, MD, Selina Chen-Kiang, PhD, Maurizio Di Liberto, PhD, Rosa Lapalombella, PhD, Kris Vaddi, PhD, Peggy Scherle, PhD, Youssef Youssef, MD, Robert A Baiocchi, MD PhD, Lapo Alinari, MD PhD

Blood (2019) 134 (Supplement_1): 4065.

https://doi.org/10.1182/blood-2019-128998

Published: 2019

Journal Articles

Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT Activators

Yuxuan Liu, PhD, Jole Fiorito, PhD, Yulissa Gonzalez, Brian Estrella, PhD, Elisa Calcagno, PhD, Elisa Zuccarello, PhD, Howook Hwang, PhD, Barry Honig, PhD, Shixian Deng, PhD, Donald Landry, MD PhD, Owen A. O'Connor, MD PhD, Ottavio Arancio, PhD, Jennifer E Amengual, MD

Blood (2019) 134 (Supplement_1): 4068.

https://doi.org/10.1182/blood-2019-125983

Published: 2019

Journal Articles

GSK1838705a, an IGF-1R/ALK Inhibitor, Overcomes Resistance to Crizotinib in ALK-Positive ALCL

Wenyu Shi, Jian-Yong Li, MD PhD

Blood (2019) 134 (Supplement_1): 4069.

https://doi.org/10.1182/blood-2019-130063

Published: 2019

Journal Articles

Inhibition of the MiR-185-PAK6-Mediated Survival and Metabolic Pathways Selectively Targets Drug-Resistant CML Stem/Progenitor Cells

Andrew Wu, BSc, Katharina Rothe, PhD, Min Chen, PhD, Hanyang Lin, PhD, Artem Babaian, PhD, Ryan Yen, BSc, Donna L. Forrest, MD, Xiaoyan Jiang, MD PhD

Blood (2019) 134 (Supplement_1): 4138.

https://doi.org/10.1182/blood-2019-127826

Published: 2019

Journal Articles

Discovery of DWP213388, a Potent ITK and BTK Selective Dual Inhibitor with Excellent Efficacy and Safety, for Treating Gvhd

Deokki Eom, BS, Jae Hun Jung, Eun Kyung KIM, PhD, Wolyoung Kim, Qingri Li, Jaehyun Jung, Sohee Im, Yong Dae Shin, Hyaejung Hyun, Joon Seok Park

Blood (2019) 134 (Supplement_1): 4426.

https://doi.org/10.1182/blood-2019-126839

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

iPLA2β Contributes to Activation of Human and Mouse Platelets Via ITAM Receptors Fcγ RIIA and GPVI

Pharmacological Inhibition of the RNA m 6 a Writer METTL3 As a Novel Therapeutic Strategy for Acute Myeloid Leukemia

A Phase 2 Study of MT-3724 to Evaluate Safety, Pharmacodynamics and Efficacy of MT-3724 for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Venetoclax Is Synergistic with Idelalisib or MK2206 Against Primary CLL Cells in an in Vitro Model of the Microenvironment

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Inhibition of Acute Leukemia By a Small Molecule KYA1797K Which Destabilize RAS and β-Catenin

Identification of Tractable Drug-like eIF4Al Inhibitors with Potent Anti-Tumor Activity

Dasatinib Inhibits FLT3 /ITD and PTPN11 mutated Acute Myeloid Leukemia Cells Overexpressing SRC Tyrosine Kinases

Pharmacological Inhibition of MAP2K7 Induces Apoptosis and Cell Cycle Arrest in T-Cell Acute Lymphoblastic Leukemia

Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax As a Therapeutic Strategy for Acute Lymphoblastic Leukemia

Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma

S-Phase Progression of North American ATLL Cells Is Critically Regulated By the Proto-Oncogene BCL6 and Targetable By PARP Inhibition

Superior Pre-Clinical Efficacy of Novel Protac Based BET Degrader in a Large Acute Myeloid Leukemia Cohort

Efficient Elimination of Acute Myeloid Leukemia Cells through Inhibition of KDM4A in Combination with PARP Inhibition

Targeting Neurotrophic Receptor Tyrosine Kinase (NTRK) Fusion Structural Homologs in Refractory Pediatric Acute Lymphoblastic Leukemia (ALL)

Targeting PRMT5 to Circumvent Acquired Ibrutinib Resistance in Mantle Cell Lymphoma

Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT Activators

GSK1838705a, an IGF-1R/ALK Inhibitor, Overcomes Resistance to Crizotinib in ALK-Positive ALCL

Inhibition of the MiR-185-PAK6-Mediated Survival and Metabolic Pathways Selectively Targets Drug-Resistant CML Stem/Progenitor Cells

Discovery of DWP213388, a Potent ITK and BTK Selective Dual Inhibitor with Excellent Efficacy and Safety, for Treating Gvhd

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only